Atezolizumab and Nab-Paclitaxel in Advanced Triple-Negative Breast Cancer.

By K. Altundağ. New England Journal of Medicine, 2019

1,544 citations recorded by the source corpus.

Subfields: Oncology, Pulmonary and Respiratory Medicine

View Paper: https://www.semanticscholar.org/paper/801678bded35377e981e171579dbb7248bf3a274

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Oncology

1. R. Edwards
2. A. Garrido-Castro
3. K. Polyak
4. Michael Montalto
5. Yongheng Chen
6. S. Leonov
7. Huajun Zhang
8. Lin Chen

In Pulmonary and Respiratory Medicine

1. R. Edwards
2. Michael Montalto
3. Yongheng Chen
4. S. Leonov
5. Huajun Zhang
6. Lin Chen
7. Na Liu
8. Yun R Li

Citations in the corpus

• Insights into molecular classifications of triple-negative breast cancer: improving patient selection for treatment (2019, background): “7month difference in the ITT population (118).”
• Cytotoxic CD8+ T cells in cancer and cancer immunotherapy (2020, background): “Atezolizumab in combination with chemotherapy was approved for advanced small-cell lung cancer(47) and for certain women with advanced triple-negative breast cancer.(48) In 98 clinical trials (n= 24,915) of PD-1 inhibitors, monotherapy was compared with combination therapy by indication and line of ”
• Digital pathology and artificial intelligence in translational medicine and clinical practice (2021, methodology): “While the use of IHC assays has led to better identi fi cation of patients who respond to I-O therapy 24 – 26 , there remains a need to more accurately quantify complex immune markers, including cell phenotypes in a spatial context, that require advanced quantitative tools to maximize the amount of…”
• Recent advances in therapeutic strategies for triple-negative breast cancer (2022, methodology): “The efficacy of atezolizumab plus nab-paclitaxel for locally advanced TNBC or mTNBC was assessed in the phase III Impassion130 trial (NCT02425891) [134].”
• Immune Checkpoint Inhibitors in Cancer Therapy (2022, background): “9 months revealed that the Atezolizumab to Nab-paclitaxel combination decreased by 40% the risk of progression or death in patients PD-L1-positive tumours in comparison with nab-paclitaxel alone [62].”